D-Dimer Testing in Pregnancy

ABSTRACT

Normal pregnancy is associated with alterations of the hemostatic system toward a hypercoagulable state. Elevated markers of coagulation and fibrinolytic system activation, such as D-dimer, indicate increased thrombin activity and increased fibrinolysis following fibrin formation throughout pregnancy. Testing for D-dimer in pregnant women could be useful for the diagnosis and prediction of a venous thromboembolic event or pregnancy-related complications and for monitoring antithrombotic treatment. This approach, however, is hampered by the fact that even an uncomplicated pregnancy in healthy women is accompanied by a substantial increase of D-dimer. Thus, prior to clinical application reference values of D-dimer according to gestational age need to be validated. A substantial increase of D-dimer during pregnancy is seen despite thromboprophylaxis with low-molecular-weight heparin (LMWH), indicating that further studies are needed to evaluate monitoring of LMWH during pregnancy and to investigate the optimal beginning and dose of LMWH thromboprophylaxis in pregnant women.

KEYWORDS

D-dimer - pregnancy

REFERENCES

• 1 Koonin L M, MacKay A P, Berg C J, Atrash H K, Smith J C. Pregnancy-related mortality surveillance-United States, 1987-1990.  MMWR CDC Surveill Summ. 1997;  46 17-36
• 2 Greer I A. Thrombosis in pregnancy: maternal and fetal issues.  Lancet. 1999;  353 1258-1265
• 3 Ginsberg J S, Brill-Edwards P, Burrows R F et al.. Venous thrombosis during pregnancy: leg and trimester of presentation.  Thromb Haemost. 1992;  67 519-520
• 4 Rosendaal F R. Risk factors for venous thrombotic disease.  Thromb Haemost. 1999;  82 610-619
• 5 Hellgren M. Hemostasis during normal pregnancy and puerperium.  Semin Thromb Hemost. 2003;  29 125-130
• 6 Eichinger S, Weltermann A, Philipp K et al.. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden.  Thromb Haemost. 1999;  82 1232-1236
• 7 Bar J, Blickstein D, Hod M, Bar-Hava I. Increased D-dimer levels in twin gestation.  Thromb Res. 2000;  98 485-489
• 8 Wells P S, Anderson D R, Ginsberg J. Assessment of deep vein thrombosis or pulmonary embolism by the combined use of clinical model and noninvasive diagnostic tests.  Semin Thromb Hemost. 2000;  26 643-656
• 9 Kelly J, Hunt B J. A clinical probability assessment and D-dimer measurement should be the initial step in the investigation of suspected venous thromboembolism.  Chest. 2003;  124 1116-1119
• 10 Van Wersch JWJ, Ubachs JMH. Blood coagulation and fibrinolysis during normal pregnancy.  Eur J Clin Chem Clin Biochem. 1991;  29 45-50
• 11 Sattar N, Greer I A, Rumley A et al.. A longitudinal study of the relationships between haemostatic, lipid, and oestradiol changes during normal human pregnancy.  Thromb Haemost. 1999;  81 71-75
• 12 Chabloz P, Reber G, Boehlen F, Hohlfeld P, de Moerlosse P. TAFI antigen and D-dimer levels during normal pregnancy and at delivery.  Br J Haematol. 2001;  115 150-152
• 13 Giavarina D, Mezzana G, Dorizzi R M, Soffiati G. Reference interval of D-dimer in pregnant women.  Clin Biochem. 2001;  34 331-333
• 14 Morse M. Establishing a normal range for D-dimer levels through pregnancy to aid in the diagnosis of pulmonary embolism and deep vein thrombosis.  J Thromb Haemost. 2004;  2 1202-1204
• 15 Epiney M, Boehlen F, Boulvain M, Reber G, Antonelli E, de Moerloose P. D-dimer levels during delivery and the postpartum.  J Thromb Haemost. 2005;  3 268-271
• 16 Brill-Edwards P, Ginsberg J S, Gent M et al.. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group.  N Engl J Med. 2000;  343 1439-1444
• 17 Pabinger I, Grafenhofer H, Kyrle P A et al.. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism.  Blood. 2002;  100 1060-1062
• 18 Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.  Thromb Haemost. 2002;  87 7-12
• 19 Eichinger S, Minar E, Bialonczyk C et al.. D-dimer levels and risk of recurrent venous thromboembolism.  JAMA. 2003;  290 1071-1074
• 20 Cadroy Y, Grandjean H, Pichon J et al.. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia.  Br J Obstet Gynaecol. 1993;  100 416-420
• 21 Bellart J, Gilabert R, Fontcuberta J, Carreras E, Miralles R M, Cabero L. Coagulation and fibrinolysis parameters in normal pregnancy and in gestational diabetes.  Am J Perinatol. 1998;  15 479-486
• 22 Proietti A B, Johnson M J, Proietti F A, Repke J T, Bell W R. Assessment of fibrin(ogen) degradation products in preeclampsia using immunoblot, enzyme-linked immunosorbent assay, and latex-based agglutination.  Obstet Gynecol. 1991;  77 696-700
• 23 Bellart J, Gilabert R, Angles A et al.. Tissue factor levels and high ratio of fibrinopeptide A: D-dimer as a measure of endothelial procoagulant disorder in pre-eclampsia.  Br J Obstet Gynaecol. 1999;  106 594-597
• 24 Nolan T E, Smith R P, Devoe L D. Maternal plasma D-dimer levels in normal and complicated pregnancies.  Obstet Gynecol. 1993;  81 235-238
• 25 Nolan T E, Smith R P, Devoe L D. A rapid test for abruptio placentae: evaluation of a D-dimer latex agglutination slide test.  Am J Obstet Gynecol. 1993;  169 265-268; discussion 268-269
• 26 Padden M O. HELLP syndrome: recognition and perinatal management.  Am Fam Physician. 1999;  60 829-836, 839 (Review)
• 27 Kobayashi T, Tokunaga N, Sugimura M, Kanayama N, Terao T. Predictive values of coagulation/fibrinolysis parameters for the termination of pregnancy complicated by severe preeclampsia.  Semin Thromb Hemost. 2001;  27 137-141
• 28 Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J S. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.  Thromb Haemost. 2000;  83 693-697
• 29 Nelson-Piercy C, Letsky E A, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk.  Am J Obstet Gynecol. 1997;  176 1062-1068
• 30 Hunt B J, Doughty H A, Majumdar G et al.. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies.  Thromb Haemost. 1997;  77 39-43
• 31 Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia.  J Thromb Haemost. 2003;  1 433-438
• 32 Gris J C, Mercier E, Quere I et al.. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder.  Blood. 2004;  103 3695-3699
• 33 Hoke M, Kyrle P A, Philipp K et al.. Prospective evaluation of coagulation activation in pregnant women receiving low-molecular weight heparin.  Thromb Haemost. 2004;  91 935-940